- Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow upSong, Yuqin; Zhou, Keshu; Li, Dengju; Hu, Jianda; Zou, Dehui; Gao, Sujun; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lyu, Fangfang; Fang, Cheng; Xu, Sheng; Zhu, Jun65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical TrialCai, Qingqing; Xia, Yi; Liu, Panpan; Zhang, Yuchen; Huang, Huiqiang; Gao, Yan; Li, Guowei; Sun, Xiuhua; Pan, Xueyi64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 2
- Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD studyFlowers, Christopher; Zinzani, Pier Luigi; Mayer, Jiri; Bijou, Fontanet; de Oliveira, Ana C.; Song, Yuqin; Zhang, Qingyuan; Merli, Michele; Bouabdallah, Krimo; Ganly, Peter S.; Zhang, Huilai; Yuen, Sam; Kingsley, Ed; Assouline, Sarit E.; Auer, Rebecca; Kim, Pil; Greenbaum, Adam; Huang, Sha; Delarue, Richard; Trotman, JudithAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis
1被引9阅读
